78 results about "Hypoglycemic Medicines" patented technology

The present invention belongs to the technical field of biological pharmacy, and in particular relates to a preparation and purification method of tetra-hydroxyl xanthone mango aglycone (norathyriol), and an application thereof in hypoglycemic medicine. Based on biological experiments, mango glycoside is used as raw material; under the condition with phenol and hydroiodic acid, carbon-carbon bonds are broken to produce the crude product of mango aglycone; the crude product is separated and purified through silica gel column chromatography so that the mango aglycone is separated; the yield rate reaches 12 percent, the purity is higher than 95 percent, and the reproduction performance is good; the IGTT of C57BL/6 normal mice is effectively improved with the norathyriol; and simultaneously the quantity of insulin secretion induced by glucose in vivo for the C57BL/6 normal mice can be improved with the norathyriol. Therefore, the mango aglycone can be applied for preparation of hypoglycemic medicine.

The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

The present invention relates to a compound medicine for preventing and curing angiocardiopathy and cerebrovascular disease, belonging to the field of chemical medicine. It is characterized by that said compound medicine includes sexual hormones medicine, lipid-reducing medicine, hypotenser, hypoglycemic medicine and anticoagulant medicine. Said compound medicine can be made into various dosage forms. Besides, said compound medicine also can be used for curing the diseases of climacteric syndrome, osteoporosis, endometrial carcinoma, diabetes and metabolic syndrome, etc.

The invention relates to a hypoglycemic medicine and a composition, and in particular relates to a compound as shown in the formula I or a solvate thereof. The structure of the composition is described in the specification. The invention further relates to a medicine composition comprising the compound and application of the medicine composition and the compound. The compound or the composition is an excellent hypoglycemic medicine.

The invention relates to a Chinese traditional hypoglycemic medicine, in particular a thirty-ingredient hypoglycemic gelatin capsule, which is prepared from thirty ingredients, including red ginseng, astragali, ganoderma lucidum, magnolia vine fruit, kudzu root, radix salviae miltiorrhizae, hemlock parsley, symbranchoid eels, dodder, black sesame seed, radix rehmanniae, radix rehmanniae preparata, blackfungus and so on, through extraction.

A 2,3,5,4'-tetrahydroxy distyrene-2-O-beta-D-glucoside used for hypoglycemic medicine is prepared from the decoction of fleece flower root through extracting, separating and purifying. It can suppress the increasement of serum cholesterol, decrease low-density serum lipoprotein cholesterol and improve activity of liver esterase.

The invention relates to a sugar-lowering drug composition and application thereof. The composition comprises 1) medicinal dosage of vildagliptin, 2) medicinal dosage of any one or combination of thiazolidinedione sugar-lowering drugs or medicinal salt thereof, sulfonylurea sugar-lowering drugs or medicinal salt thereof or biguanide sugar-lowering drugs or medicinal salt thereof and 3) B vitamins. The invention relates to application of the sugar-lowering drug composition to preparing the drugs for treating and/or controlling diabetes or diabetic complications. The composition can effectively overcome the defect that type 2 diabetes can not be controlled by singly taking the commonly used sugar-lowering drugs or vildagliptin in the prior art and simultaneously addition of the B vitamins is conductive to enhancing the treatment effect of the drug, effectively controlling the blood sugar, protecting the endothelial cell functions in a synergic manner, slowing rising of plasma homocysteine of the diabetes patients, especially the diabetes patients associated with chronic complications and reducing the diabetic complications.

The invention relates to a newly-developed medicine compound for diabetes which contains sulfonylureas drug for diabetes or a bioactive metabolite of the sulfonylureas drug for diabetes or pharmaceutical salt of the sulfonylureas drug for diabetes, and thiazolidinedione drug for diabetes or pharmaceutical salt and vitamin B of the thiazolidinedione drug for diabetes. The compound contains the sulfonylureas drug for diabetes of therapy dose or the bioactive metabolite of the sulfonylureas drug for diabetes or the pharmaceutical salt of the sulfonylureas drug for diabetes, the thiazolidinedione drug for diabetes of therapy dose or the pharmaceutical salt and therapy dose of vitamin B of the thiazolidinedione drug for diabetes or compound which is related to the thiazolidinedione drug for diabetes and has similar bioactivity and pharmaceutical carrier or excipient. The invention also relates to the purpose of the compound in preparation of drug for treating diabetes or preventing diabetes complication, belonging to the pharmaceutical field.

The present invention relates to kidney benefiting hypoglycemic medicine composition and its preparation process. The kidney benefiting hypoglycemic medicine composition is prepared with 31 kinds of Chinese medicinal materials, including angelica, ginseng, figwort, beach silvertop root, Chinese yam, etc. and through washing, stoving, crushing, sieving and other steps. It has the functions of nourishing lung and kidney, clearing away stomach heat, tranquilizing, clearing away heat and toxic material and reducing blood sugar. It can also remit complication and strengthen immunity.

A hypoglycemic medicine in the form of particles is prepared from chromium pyridylfomate, Se-enriched yeast, the extracts of 6 Chinese-medicinal materials including ginseng leaf, astragalus root, pueraria root, red sage root, etc. Its preparing process is also disclosed.

The invention relates to phytoremediation technology for treating heavy metal waste water, in particular to a remediating method of heavy metal waste water containing copper by synergistic action of commelinaceae plant and microorganic microbial inoculum. A biological floating bed made from common dayflower is put in waste water polluted by copper which is added with a probiotic agent, pollution by copper is removed by absorption and enrichment of the plant on heavy metal copper, the action of the microbial inoculum is to antagonize putrefying bacteria and secretes auxin substance to improve the biomass of common dayflower, and the harvested common dayflower is used as a raw material for extracting hypoglycemic medicine deoxynojirimycin (shortened as DNJ), thus the remediating process becomes the process of managing pollution, beautifying the environment and obtaining DNJ raw material.

The invention provides a Method for rapidly detecting a sulfonylomocznik compound added in hypoglycemic medicines, health products and foodstuff and applications thereof. The method comprises selecting a tested sample of once taking amount, adding 3ml dichloromethane, shaking out to dissolve, stewing for a moment, and filtrating; selecting 2ml of filtrate, adding 10mg or 20mg of vanillin solid , then adding 2ml of concentrated sulfuric acid solution, heating for 1min in a micro boiling water bath until an upper dichloromethane layer is completely volatilized; and cooling the solution to room temperature, slowly adding 5ml of ethanol, immediately observing color change of a liquid separation layer and an upper layer solution, slightly shaking up if the liquid separating layer changes purple, and determining that sulfonylomocznik compound is added when the liquid separation layer and the upper layer solution change blue. The method and a used kit have advantages of low analysis cost, strong anti-interference capability, no need of special equipment, high sensitivity, obvious easy observation and judgement of chromogenic result, and high correct rate of examination conclusion, and are suitable for on-site rapid detection.

The present invention relates to a medicine composition containing hypoglycemic medicine (mainly including thiazolidione, biquanide or alpha-glycosidase inhibitor) and antiplatelet medicine (mainly including aspirin or clopidogrel). Said medicine composition contains hypoglycemic medicine or its medicinal salt with effective dose and medicinal carrier or excipient. Said invention also provides the application of said medicine composition in preparation of medicine for curing the diseases of hypertension, diabetes, inflammation and atherosclerosis, etc.

The invention discloses a novel alpha-glucosidase active inhibitor, belonging to the field of functional factors of functional foods and medicines; tea pigments in the invention can be used for strongly inhibiting alpha-glucosidase activity; the IC50 of alcohol-soluble theaflavin, the IC50 of thearubigin and the IC50 of theabrownin are 3.94 mu g/ml, 3.24 mu g/ml and 75.43 mu g/ml respectively; the half inhibition rate IC 50 of alcohol-soluble theaflavin, the half inhibition rate IC50 of thearubigin and the half inhibition rate IC50 of theabrownin are 8.19 mu g/ml, 4.50 mu g/ml and 6.98 mu g/ml respectively; the alpha-glucosidase inhibition effect of alcohol-soluble tea pigments or water-soluble tea pigments is far prior to that of the common hypoglycemic medicine, namely acarbose (acarbose IC50=1.04 mg/ml); and therefore, the novel alpha-glucosidase active inhibitor can be used as a food additive or a medicine for treating diabetes. Because of being pure natural pigments extracted from tea leaves, the tea pigments are safe, nontoxic and better in blood sugar decreasing effect; the advantages of the tea pigments are imponderable by acarbose; and therefore, the novel alpha-glucosidase active inhibitor has the application prospect for being developed into a health-care product or a novel hypoglycaemic medicine.

The invention discloses a mulberry resource long-acting hypoglycemic medicine composition as well as granules and a preparation method thereof. The mulberry resource long-acting hypoglycemic medicine composition comprises a mulberry resource hypoglycemic activity extract, a pueraria root flavonoid extract, gelatin and microbial transglutaminase; and the preparation method of the mulberry resource long-acting hypoglycemic granules comprises the following steps: preparing the mulberry resource hypoglycemic activity extract, preparing the pueraria root flavonoid extract, preparing the hypoglycemic granules, and the like. The mulberry resource hypoglycemic medicine composition and the granules prepared by using the method disclosed by the invention can be used for controlling the level of postprandial blood sugar in multi-way and long-acting modes.

The invention discloses a hypoglycemic effective position for sweet osmanthus, a preparation method and application thereof. The effective position is an ethyl acetate position and/or a normal butanol position which is obtained by taking sweet osmanthus as a raw material, and after extraction of condensate by crushing, cold soaking, filtration and vacuum recovery. The hypoglycemic effective position, namely ethyl acetate extract, has obvious activity in inhibiting alpha-glucosaccharase; and hypoglycemic effective constituents obtained from the effective position, namely an ursolic acid and an oleanolic acid, also have high activity in inhibiting the alpha-glucosaccharase, wherein the IC50 value (the half inhibition ratio) is 0.003Mug.m L <-1>, and the activity of the ursolic acid and the oleanolic acid in inhibiting the alpha-glucosaccharase is better than that of a hypoglycemic medicine - acarbose (the IC50 value is 1,081.27 Mug.m L <-1>) which is commonly used on clinic under the same condition.

The present invention is one kind of botanical hypoglycemic medicine for treating type-II diabetes and its preparation process. The botanical hypoglycemic medicine is prepared with cassia and waternut in the weight ratio of 0.8-1.2 to 3.5-4.5. The preparation process include the following steps: preparing fine cassia powder, extracting volatile cassia oil, preparing fine waternut powder, mixing, pelletizing and encapsulating or preparing oral liquid. The botanical hypoglycemic medicine has determined hypoglycemic effect, no obvious side effect and other advantages.

The invention discloses a traditional Chinese medicine composition for treating diabetes. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 25-35 parts of astragalus membranaceus, 20-30 parts of white peony root , 15-20 parts of rhizoma anemarrhenae, 12-16 parts of poria cocos, 12-16 parts of polygonatum kingianum , 5-10 parts of radix ophiopogonis, 5-10 parts of sedum verticallatum, 5-10 parts of euphorbia humifusa, 5-10 parts of Chinese ixora flower, 5-10 parts of Chinese trumpet creeper, 5-10 parts of caulis bambusae in taeniis, 4-8 parts of dens draconis, 4-8 parts of rabdosia rubescens, 3-6 parts of caulis kadsurae and 8-10 parts of liquorice. The invention discloses a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition for treating diabetes disclosed by the invention is pure traditional Chinese medicine preparation, has a remarkable curative effect and not obvious toxic and side effect on diabetes caused by endocrine dyscrasia, can be used for overcoming the problems that the conventional medicament for treating the diabetes is high in use amount of hypoglycemic medicines and insulin and is higher in cost and greater in side effect on a human body after long-term use, is quick in effect taking, extract in curative effect, wide in medicinal herb resource ad low in cost, has an effective rate as high as 92% and a low complication occurrence rate, can be used for treating both manifestation and root cause of disease, and has a good long-term effect.